NightHawk Biosciences Inc (NHWK)

[Titan V]

I was researching on bladder cancer too and came across the following. It will be interesting if Heat can produce better data than Roche or work together.

Roche's new PD-L1 bladder cancer drug could be on the market by September
http://www.fiercebiotech.com/regulatory/roche-s-new-pd-l1-bladder-cancer-drug-could-be-on-market-by-september

Earlier this year...
New Roche PD-L1 Tecentriq shines in study of untreated bladder cancer patients
http://www.fiercepharma.com/pharma/new-roche-med-tecentriq-shines-study-untreated-bladder-cancer-patients

FDA grants Roche’s cancer immunotherapy Tecentriq (atezolizumab) accelerated approval for people with a specific type of advanced bladder cancer
http://www.roche.com/media/store/releases/med-cor-2016-05-19.htm

Btw, Heat Biologics Expands Scientific and Clinical Advisory Board With Appointments of Drs. Holbrook Kohrt and Kapil Dhingra
http://www.heatbio.com/newsroom/press-releases/detail/501/heat-biologics-expands-scientific-and-clinical-advisory

Dr. Dhingra has over 25 years of experience in oncology clinical research and drug development, including nine years at Roche Pharmaceuticals, where he played a key role in the expansion of Roche Oncology. He served in several management positions at Roche, including Vice President, Head, Oncology Disease Biology Leadership Team, and Head, Oncology Clinical Development.

His LinkedIn is interesting too. He has been on the BOD for 3 companies that were sold for over $1B and another one for $557M.
https://www.linkedin.com/in/kapil-dhingra-3811645